Overview
Laura Logsdon is of counsel in the Litigation Department. Based in the New York office, Laura represents leaders in the pharmaceutical, medical device, and technology industries in complex commercial and intellectual property litigation before United States District Courts, United States Courts of Appeal, and the International Trade Commission. In this part of her practice, she has litigated patent, trade secret, trade dress, antitrust, and IP licensing disputes. A multidisciplinary litigator, Laura also appears regularly in New York State courts on behalf of hedge funds, private equity firms, investment banks, and other financial institutions. She has experience in bench and jury trials, and clients rely on her to help them enforce valuable rights, and to defend against threatened or looming claims, without the risks and expenses of litigation. Prior to joining Paul Hastings, Laura worked at a leading international law firm.
Representations
- Argued and won an appeal before the U.S. Court of Appeals for the Second Circuit for NielsenIQ in a contract, unfair competition and trade-secret matter concerning the development and commercialization of consumer panel technology.
- Represented a New York-based hedge fund in a high-stakes dispute arising from an aviation sales and leasing joint venture.
- Represented LG Electronics in a contract, antitrust, and FRAND/IP dispute against Dolby Laboratories, Inc. Resolved during the pendency of a preliminary injunction brought by LG Electronics.
- Represented Mahindra & Mahinda, an India-based vehicle manufacturer in an appeal of ITC’s Section 337 trade dress infringement determinations. The Federal Circuit ruled that Mahindra’s redesigned vehicle did not infringe the claimant’s claimed trade dress in “jeep” vehicles, giving the client a significant win and allowing it to continue importing its products into the U.S.
- Represented Pfizer in litigation against Merck concerning alleged misappropriation of trade secrets and confidential business information in the development of multi-conjugate pneumococcal vaccines.
- Represented leading pharmaceutical company in arbitration proceedings related to trade-secret theft.
- Represented Abiomed in a patent infringement dispute regarding the company’s core product, the Impella® line of heart pumps. After a favorable Markman ruling, the Court granted summary judgment of non-infringement, giving Abiomed a complete victory and clearing the way for the company’s $16.6 billion acquisition by Johnson & Johnson.